Printer Friendly

LAWRENCE A. LOEB JOINS NEORX SCIENTIFIC ADVISORY BOARD

 LAWRENCE A. LOEB JOINS NEORX SCIENTIFIC ADVISORY BOARD
 SEATTLE, March 19 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX)


announced today that Lawrence A. Loeb, M.D., Ph.D., former president of the American Association for Cancer Research, has joined the company's Scientific Advisory Board, bringing the total board members to six. Loeb is a recognized authority in the molecular biology of cancer.
 Loeb obtained his Ph.D. in biochemistry at the University of California-Berkeley and his M.D. from New York University. He has had academic appointments at the National Cancer Institute, University of Pennsylvania, Institute for Cancer Research-Philadelphia and the University of Washington. He has received several awards including Fellow, American Association for the


Advancement of Science and Outstanding Investigator - National Cancer Institute, has served on numerous NIH advisory committees and has chaired several international scientific meetings. He is currently professor, Department of Pathology and director, Joseph Gottstein Memorial Cancer Research Laboratory at the University of Washington.
 "Lawrence Loeb's expertise in mechanisms of carcinogenesis mutagenesis and molecular biology of cancer adds to the breadth of our Advisory Board," said Alan R. Fritzberg, Ph.D., NeoRx vice president and chief scientific officer. "As NeoRx develops new therapeutic targets and expands its technology base, Dr. Loeb's expertise will be invaluable."
 NeoRx Corporation develops targeted biopharmaceutical products to detect and treat disease. The company has three cancer therapy trials in progress, has filed for marketing approval with the FDA for two OncoTrac(R) cancer imaging products and has completed a phase III trial for a third. Targeted biopharmaceuticals to treat cancer, restenosis after angioplasty and autoimmune diseases are in pre-clinical testing.
 -0- 3/19/92
 /CONTACT: Robert M. Littauer, vice president, chief financial officer and treasurer of NeoRx, 206-286-2519; or Anthony J. Russo or Susan A. Noonan of Noonan/Russo Communications, 212-979-9180, for NeoRx/
 (NERX) CO: NeoRx Corporation ST: Washington IN: MTC SU: PER


GK-OS -- NY018 -- 9543 03/19/92 09:31 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 19, 1992
Words:319
Previous Article:NEWBRIDGE PRODUCTS SPECIFIED BY MCI IN FAA LINCS CONTRACT
Next Article:/C O R R E C T I O N -- JHM MORTGAGE SECURITIES L.P./
Topics:


Related Articles
NEORX INCREASES SIZE OF ITS BOARD OF DIRECTORS
Acacia Biosciences Names Stewart Scherer, Ph.D. Vice President of Bioinformatics

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters